217 related articles for article (PubMed ID: 26512140)
1. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
Henrich TJ; Hanhauser E; Harrison LJ; Palmer CD; Romero-Tejeda M; Jost S; Bosch RJ; Kuritzkes DR
J Infect Dis; 2016 Mar; 213(5):766-70. PubMed ID: 26512140
[TBL] [Abstract][Full Text] [Related]
2. Relationship between CCR5
Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
[TBL] [Abstract][Full Text] [Related]
3. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
[TBL] [Abstract][Full Text] [Related]
4. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
5. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
6. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
[TBL] [Abstract][Full Text] [Related]
7. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
Wit FW; van Rij RP; Weverling GJ; Lange JM; Schuitemaker H
J Infect Dis; 2002 Dec; 186(12):1726-32. PubMed ID: 12447757
[TBL] [Abstract][Full Text] [Related]
8. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
[TBL] [Abstract][Full Text] [Related]
9. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
10. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
[TBL] [Abstract][Full Text] [Related]
11. Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.
Scully EP; Gandhi M; Johnston R; Hoh R; Lockhart A; Dobrowolski C; Pagliuzza A; Milush JM; Baker CA; Girling V; Ellefson A; Gorelick R; Lifson J; Altfeld M; Alter G; Cedars M; Solomon A; Lewin SR; Karn J; Chomont N; Bacchetti P; Deeks SG
J Infect Dis; 2019 Mar; 219(7):1084-1094. PubMed ID: 30371873
[TBL] [Abstract][Full Text] [Related]
12. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type.
Bogner JR; Lutz B; Klein HG; Pollerer C; Troendle U; Goebel FD
HIV Med; 2004 Jul; 5(4):264-72. PubMed ID: 15236615
[TBL] [Abstract][Full Text] [Related]
13. Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.
Liu S; Kong C; Wu J; Ying H; Zhu H
PLoS One; 2012; 7(4):e35020. PubMed ID: 22496885
[TBL] [Abstract][Full Text] [Related]
14. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex.
van Rij RP; Portegies P; Hallaby T; Lange JM; Visser J; de Roda Husman AM; van 't Wout AB; Schuitemaker H
J Infect Dis; 1999 Sep; 180(3):854-7. PubMed ID: 10438379
[TBL] [Abstract][Full Text] [Related]
15. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
[TBL] [Abstract][Full Text] [Related]
16. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
Gorry PR; Dunfee RL; Mefford ME; Kunstman K; Morgan T; Moore JP; Mascola JR; Agopian K; Holm GH; Mehle A; Taylor J; Farzan M; Wang H; Ellery P; Willey SJ; Clapham PR; Wolinsky SM; Crowe SM; Gabuzda D
Virology; 2007 May; 362(1):163-78. PubMed ID: 17239419
[TBL] [Abstract][Full Text] [Related]
17. Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.
Calin R; Fourati S; Schneider L; Gautheret-Dejean A; Lambert-Niclot S; Wirden M; Carcelain G; Katlama C; Marcelin AG; Tubiana R
J Antimicrob Chemother; 2015 Jan; 70(1):317-9. PubMed ID: 25239464
[No Abstract] [Full Text] [Related]
18. Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor.
Gornalusse GG; Mummidi S; Gaitan AA; Jimenez F; Ramsuran V; Picton A; Rogers K; Manoharan MS; Avadhanam N; Murthy KK; Martinez H; Molano Murillo A; Chykarenko ZA; Hutt R; Daskalakis D; Shostakovich-Koretskaya L; Abdool Karim S; Martin JN; Deeks SG; Hecht F; Sinclair E; Clark RA; Okulicz J; Valentine FT; Martinson N; Tiemessen CT; Ndung'u T; Hunt PW; He W; Ahuja SK
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4762-71. PubMed ID: 26307764
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review.
Smoleń-Dzirba J; Rosińska M; Janiec J; Beniowski M; Cycoń M; Bratosiewicz-Wąsik J; Wąsik TJ
AIDS Rev; 2017 Dec; 19(4):219-230. PubMed ID: 28534889
[TBL] [Abstract][Full Text] [Related]
20. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
